Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds

Journal of Alzheimer's Disease

Volumn 48, Issue 3, 2015, Pages 711-720

  Duits, Flora H ^a   Hernandez Guillamon, Mar ^b   Montaner, Joan ^b,c   Goos, Jereon D C ^a   Montañola, Alex ^b   Wattjes, Mike P ^d   Barkhof, Frederik ^d   Scheltens, Philip ^a   Teunissen, Charlotte E ^d   Van Der Flier, Wiesje M ^a   Mroczko, Barbara ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Institut de Recerca   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; cerebral amyloid angiopathy; cerebrospinal fluid; matrix metalloproteinases; microbleeds; tissue inhibitors of matrix metalloproteinases

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; STROMELYSIN 2; TAU PROTEIN; THREONINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MAPT PROTEIN, HUMAN; MATRIX METALLOPROTEINASE; PEPTIDE FRAGMENT; TISSUE INHIBITOR OF METALLOPROTEINASE;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID-TO-PLASMA RATIO; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PROTEIN PHOSPHORYLATION; BLOOD; BRAIN; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; BRAIN; CEREBRAL HEMORRHAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84943747983     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143186     Document Type: Article

References (48)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Knudsen KA, Rosand J, Karluk D, Greenberg SM (2001) Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria. Neurology 56, 537-539.
3. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi SR, Warach S, Launer LJ, van BuchemMA, Breteler MM (2009) Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol 8, 165-174.
4. Attems J, Jellinger KA, Lintner F (2005) Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 110, 222-231.
5. Cordonnier C, van der Flier WM (2011) Brain microbleeds and Alzheimer's disease: Innocent observation or key player? Brain 134, 335-344.
6. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD experience, Part XV. Neurology 46, 1592-1596.
7. Goos JD, Teunissen CE, Veerhuis R, Verwey NA, Barkhof F, Blankenstein MA, Scheltens P, van der Flier WM (2012) Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiol Aging 33, 1011-1019.
8. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2, 502-511.
9. Wisniewski HM, Vorbrodt AW, Wegiel J (1997) Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann N Y Acad Sci 826, 161-172.
10. Farrall AJ, Wardlaw JM (2009) Blood-brain barrier: Ageing and microvascular disease-systematic review and metaanalysis. Neurobiol Aging 30, 337-352.
11. Carrano A, Hoozemans JJ, van d V, Rozemuller AJ, van HJ, de Vries HE (2011) Amyloid Beta induces oxidative stressmediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15, 1167-1178.
12. Cuadrado E, Rosell A, Penalba A, Slevin M, Varez-Sabin J, Ortega-Aznar A, Montaner J (2009) Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: A combined laser microdissection and protein array study. J Proteome Res 8, 3191-3197.
13. Hernandez-Guillamon M, Delgado P, Ortega L, Pares M, Rosell A, Garcia-Bonilla L, Fernandez-Cadenas I, Borrell-Pages M, Boada M, Montaner J (2009) Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25-35 fragment. J Neurosci Res 87, 2115-2125.
14. Konnecke H, Bechmann I (2013) The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol 2013, 914104.
15. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8, 205-216.
16. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloidbeta peptide (1-40). J Neurosci 16, 7910-7919.
17. Deb S, Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66, 1641-1647.
18. Lee JM, Yin KJ, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J (2003) Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 54, 379-382.
19. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM(2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281, 24566-24574.
20. Hernandez-Guillamon M, Martinez-Saez E, Delgado P, Domingues-Montanari S, Boada C, Penalba A, Boada M, Pagola J, Maisterra O, Rodriguez-Luna D, Molina CA, Rovira A, varez-Sabin J, Ortega-Aznar A, Montaner J (2012) MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. Brain Pathol 22, 133-141.
21. Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 43, 191-196.
22. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA (2004) Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 35, e159-e162.
23. Mlekusch R, Humpel C (2009) Matrix metalloproteinases-2 and-3 are reduced in cerebrospinal fluid with low betaamyloid1-42 levels. Neurosci Lett 466, 135-138.
24. Martin-Aragon S, Bermejo-Bescos P, Benedi J, Felici E, Gil P, Ribera JM, VillarAM(2009) Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochem Res 34, 373-378.
25. Horstmann S, Budig L, Gardner H, Koziol J, Deuschle M, Schilling C, Wagner (2010) Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr 22, 966-972.
26. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis 27, 665-676.
27. Lim NK, Villemagne VL, Soon CP, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li QX (2011) Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. J Alzheimers Dis 26, 779-786.
28. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, van Berckel BN, Stam CJ, Barkhof F, Visser PJ, van EE, Scheltens P (2014) Optimizing patient care and research: The Amsterdam Dementia Cohort. J Alzheimers Dis 41, 313-327.
29. van der Vlies, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der FlierWM(2009) CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 72, 1056-1061.
30. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
31. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A et al. (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
32. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 42, 2672-2713.
33. Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, Teunissen CE (2013) Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimers Dement 9, 276-283.
34. Goos JD, van der Flier WM, Knol DL, Pouwels PJ, Scheltens P, Barkhof F, Wattjes MP (2011) Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. Stroke 42, 1894-1900.
35. Benedictus MR, Goos JD, Binnewijzend MA, Muller M, Barkhof F, Scheltens P, Prins ND, van der Flier WM (2013) Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiol Aging 34, 2488-2494.
36. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1. 5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149, 351-356.
37. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA (1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. J Neurol 242, 557-560.
38. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36, 268-272.
39. Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC (2014) Cerebral microbleeds: A review of clinical, genetic, and neuroimaging associations. Front Neurol 4, 205.
40. Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 26, 10939-10948.
41. Murray MY, Birkland TP, Howe JD, Rowan AD, Fidock M, Parks WC, Gavrilovic J (2013) Macrophage migration and invasion is regulated by MMP10 expression. PLoS One 8, e63555.
42. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 6, e18850.
43. Nuttall RK, Silva C, HaderW, Bar-Or A, Patel KD, Edwards DR, Yong VW (2007) Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia 55, 516-526.
44. Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, Beal MF (2003) Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 207, 71-76.
45. Hartz AM, Bauer B, Soldner EL, Wolf A, Boy S, Backhaus R, Mihaljevic I, Bogdahn U, Klunemann HH, Schuierer G, Schlachetzki F (2012) Amyloid-beta contributes to bloodbrain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43, 514-523.
46. van de Haar HJ, Burgmans S, Hofman PA, Verhey FR, Jansen JF, Backes WH (2015) Blood-brain barrier impairment in dementia: Current and future in vivo assessments. Neurosci Biobehav Rev 49, 71-81.
47. Rouy D, Ernens I, Jeanty C, Wagner DR (2005) Plasma storage at ?80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338, 294-298.
48. Tarr GP, Williams MJ, Phillips LV, van Rij AM, Jones GT (2011) Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at ?80 degrees C. Clin Biochem 44, 1346-1348.